Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
PRAN's Cash-to-Debt is ranked higher than
94% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. PRAN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PRAN' s Cash-to-Debt Range Over the Past 10 Years
Min: 16.62  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.94
PRAN's Equity-to-Asset is ranked higher than
88% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PRAN: 0.94 )
Ranked among companies with meaningful Equity-to-Asset only.
PRAN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.73  Med: 0.89 Max: 0.99
Current: 0.94
0.73
0.99
Interest Coverage No Debt
PRAN's Interest Coverage is ranked higher than
93% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PRAN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PRAN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 5.03
Beneish M-Score: -3.38
WACC vs ROIC
3.67%
-543.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -5174.44
PRAN's Operating Margin % is ranked lower than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. PRAN: -5174.44 )
Ranked among companies with meaningful Operating Margin % only.
PRAN' s Operating Margin % Range Over the Past 10 Years
Min: -8127.81  Med: -4654.68 Max: -1936.45
Current: -5174.44
-8127.81
-1936.45
Net Margin % -5670.68
PRAN's Net Margin % is ranked lower than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. PRAN: -5670.68 )
Ranked among companies with meaningful Net Margin % only.
PRAN' s Net Margin % Range Over the Past 10 Years
Min: -5713.64  Med: -3493.34 Max: -1757.71
Current: -5670.68
-5713.64
-1757.71
ROE % -27.39
PRAN's ROE % is ranked higher than
57% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. PRAN: -27.39 )
Ranked among companies with meaningful ROE % only.
PRAN' s ROE % Range Over the Past 10 Years
Min: -175.24  Med: -81.47 Max: -15.33
Current: -27.39
-175.24
-15.33
ROA % -25.30
PRAN's ROA % is ranked higher than
54% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. PRAN: -25.30 )
Ranked among companies with meaningful ROA % only.
PRAN' s ROA % Range Over the Past 10 Years
Min: -139.67  Med: -63.93 Max: -14.1
Current: -25.3
-139.67
-14.1
ROC (Joel Greenblatt) % -451.57
PRAN's ROC (Joel Greenblatt) % is ranked lower than
51% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. PRAN: -451.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRAN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21719.66  Med: -2233.19 Max: -249.26
Current: -451.57
-21719.66
-249.26
3-Year Revenue Growth Rate -100.00
PRAN's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. PRAN: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRAN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -37 Max: 152
Current: -100
0
152
3-Year EBITDA Growth Rate -25.10
PRAN's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. PRAN: -25.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRAN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -24 Max: 28.3
Current: -25.1
0
28.3
3-Year EPS without NRI Growth Rate -23.30
PRAN's 3-Year EPS without NRI Growth Rate is ranked lower than
65% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. PRAN: -23.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRAN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -13.3 Max: 71
Current: -23.3
0
71
GuruFocus has detected 3 Warning Signs with Prana Biotechnology Ltd $PRAN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRAN's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

PRAN Guru Trades in

Q3 2016

PRAN Guru Trades in Q3 2016

Jim Simons 19,217 sh (New)
» More
Q4 2016

PRAN Guru Trades in Q4 2016

Jim Simons 16,295 sh (-15.21%)
» More
Q1 2017

PRAN Guru Trades in Q1 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PRAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:ASX:ACW, ASX:ACR, ASX:OCC, ASX:NOX, ASX:RGS, ASX:BOT, ASX:RAC, ASX:CDY, ASX:SUD, ASX:POH, ASX:BTC, ASX:IMC, ASX:IVQ, ASX:IMU, ASX:1AD, ASX:PAR, ASX:FTT, ASX:HCT, ASX:DXB, ASX:RNO » details
Traded in other countries:PBT.Australia, PBNN.Germany, PRNAF.USA,
Headquarter Location:Australia
Prana Biotechnology Ltd is engaged in the development of therapeutic drugs designed to treat the causes of degeneration of the brain as the aging process progresses including Alzheimer's disease, Huntington's disease and Parkinson's disease.

Prana Biotechnology Ltd was incorporated on November 11, 1997. The Company is a development stage company at an early stage in the development of its pharmaceutical products. The Company's activities include research into Alzheimer 's disease and other age-related degenerative disorders. Its compound PBT2, is manufactured by Dr. Reddys based in Hyderabad, India. It competes with pharmaceutical companies, biotechnoloy firms, universities and research institutions. The Company is subject to governmental laws and regulations.

Ratios

vs
industry
vs
history
PB Ratio 1.42
PRAN's PB Ratio is ranked higher than
93% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. PRAN: 1.42 )
Ranked among companies with meaningful PB Ratio only.
PRAN' s PB Ratio Range Over the Past 10 Years
Min: 0.65  Med: 6.8 Max: 66.84
Current: 1.42
0.65
66.84
EV-to-EBIT -1.42
PRAN's EV-to-EBIT is ranked higher than
99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. PRAN: -1.42 )
Ranked among companies with meaningful EV-to-EBIT only.
PRAN' s EV-to-EBIT Range Over the Past 10 Years
Min: -68.9  Med: -4.5 Max: 1
Current: -1.42
-68.9
1
EV-to-EBITDA -1.42
PRAN's EV-to-EBITDA is ranked higher than
99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. PRAN: -1.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRAN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -69.1  Med: -4.5 Max: 1
Current: -1.42
-69.1
1
EV-to-Revenue 74.80
PRAN's EV-to-Revenue is ranked lower than
99.99% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. PRAN: 74.80 )
Ranked among companies with meaningful EV-to-Revenue only.
PRAN' s EV-to-Revenue Range Over the Past 10 Years
Min: -35.1  Med: 113.3 Max: 1925.8
Current: 74.8
-35.1
1925.8
Current Ratio 15.88
PRAN's Current Ratio is ranked higher than
81% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. PRAN: 15.88 )
Ranked among companies with meaningful Current Ratio only.
PRAN' s Current Ratio Range Over the Past 10 Years
Min: 4.11  Med: 6.44 Max: 15.88
Current: 15.88
4.11
15.88
Quick Ratio 15.88
PRAN's Quick Ratio is ranked higher than
82% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. PRAN: 15.88 )
Ranked among companies with meaningful Quick Ratio only.
PRAN' s Quick Ratio Range Over the Past 10 Years
Min: 4.11  Med: 6.44 Max: 15.88
Current: 15.88
4.11
15.88
Days Sales Outstanding 8.00
PRAN's Days Sales Outstanding is ranked higher than
94% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. PRAN: 8.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRAN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.85  Med: 5184.71 Max: 13449.32
Current: 8
0.85
13449.32

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.00
PRAN's 3-Year Average Share Buyback Ratio is ranked higher than
51% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. PRAN: -3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRAN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.7  Med: -16.6 Max: 0
Current: -3
-144.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.54
PRAN's Price-to-Net-Cash is ranked higher than
96% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. PRAN: 1.54 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PRAN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.07  Med: 6.5 Max: 43
Current: 1.54
1.07
43
Price-to-Net-Current-Asset-Value 1.54
PRAN's Price-to-Net-Current-Asset-Value is ranked higher than
96% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. PRAN: 1.54 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PRAN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 6.38 Max: 43
Current: 1.54
1.07
43
Price-to-Tangible-Book 1.54
PRAN's Price-to-Tangible-Book is ranked higher than
95% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. PRAN: 1.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PRAN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.64  Med: 4.94 Max: 42.16
Current: 1.54
0.64
42.16
Earnings Yield (Greenblatt) % -69.19
PRAN's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. PRAN: -69.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRAN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -17325.4  Med: -20.2 Max: 316.4
Current: -69.19
-17325.4
316.4

More Statistics

Revenue (TTM) (Mil) $0.10
EPS (TTM) $ -0.63
Beta0.22
Short Percentage of Float0.00%
52-Week Range $1.52 - 5.14
Shares Outstanding (Mil)8.90 (ADR)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}